RxDoctor Payments Data

Jianqing Li, MD

Clinical Cardiac Electrophysiology · Mineola, NYNPI 1487856217

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,563 of the $27,527 with a category attached, or 67.4%. 11 manufacturers reported payments, led by Boston Scientific at 50.6% of the total. Reporting peaked in 2024 at $8,462 and has fallen 95.2% since, to $410 in 2025.

$27,527in general payments, 2019–2025

Across 124 payments — averaging $221.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Medical Device Business Services, Inc.$10K
  • Medtronic$2K
  • Biosense Webster, Inc.$1K
  • Philips North America LLC$247
  • Pfizer$91
  • plus $146 from 5 others
$87,323in research payments, 2019–2025

Across 9 payments — averaging $9702.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$87K

What the payments were for

  • Consulting fees$18,56367%
  • Travel & lodging$4,72917%
  • Food & beverage$4,23515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,527 in reported general payments places this provider in the 55th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$192,566
Medicare patients
878
Services billed
2,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$175,388
XareltoRivaroxaban47$58,086
Dofetilide13$5,159
Metoprolol Succinate221$3,266
Flecainide Acetate34$1,451
SotalolSotalol Hcl55$927
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$785
Mexiletine Hcl14$763
Amiodarone Hcl20$573
Carvedilol18$269
Lisinopril53$265
Metoprolol Tartrate41$221
Losartan Potassium14$154
Atorvastatin Calcium30$147
Pantoprazole Sodium14$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$175,388177 claims
Johnson & JohnsonXarelto$55$58,08647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Mineola

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →